| Title |
Expanding role of lenalidomide in hematologic malignancies
|
|---|---|
| Published in |
Cancer Management and Research, May 2015
|
| DOI | 10.2147/cmar.s81310 |
| Pubmed ID | |
| Authors |
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani |
| Abstract |
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 52 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 21% |
| Student > Ph. D. Student | 9 | 17% |
| Researcher | 7 | 13% |
| Student > Master | 4 | 8% |
| Student > Bachelor | 3 | 6% |
| Other | 11 | 21% |
| Unknown | 8 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 36% |
| Agricultural and Biological Sciences | 9 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Chemistry | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 May 2015.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Cancer Management and Research
#793
of 2,074 outputs
Outputs of similar age
#168,907
of 278,920 outputs
Outputs of similar age from Cancer Management and Research
#7
of 8 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,074 research outputs from this source. They receive a mean Attention Score of 3.5. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,920 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.